Federal Register / Vol. 72, No.

230 / Friday, November 30, 2007 / Notices 67737

developmental form to assess audience targeted audiences, the frequency with Latino, or men who have sex with men;
comprehension, reactions, and which publications, products, and healthcare providers; representatives of
perceptions. The information obtained programs need to be modified is organizations disseminating HIV-related
from audience research and pretesting reduced. Frequency of Response: On messages or materials. The annual
results in more effective messages, occasion. Affected Public: Individuals. reporting burden is shown in the table
materials, and programmatic strategies. Type of Respondents: Adults at risk for below. There are no Capital Costs to
By maximizing the effectiveness of these HIV/AIDS, particularly those who are report. There are no Operating or
messages and strategies for reaching Black/African-American, Hispanic/ Maintenance Costs to report.

Estimated Estimated
Estimated Average
number of total annual
Type of respondents number of burden hours
responses per burden hours
respondents per response
respondent requested

At-risk Adults ................................................................................................ 3,374 1 .3422 1,155

Healthcare providers .................................................................................... 50 1 .75 37.5
Organization Gatekeepers ........................................................................... 75 1 .50 37.5

Total ...................................................................................................... 3,499 ........................ .......................... 1,230

Request for Comments: Written E-mail your request, including your Global Health Research Initiative
comments and/or suggestions from the address to kripkek@niaid.nih.gov. Program for New Foreign Investigators
public and affected agencies should Comments Due Date: Comments (GRIP) to date, assess the programs
address one or more of the following regarding this information collection are alignment with new strategic goals of
points: (1) Evaluate whether the best assured of having their full effect if the FIC, and identify potential
proposed collection of information is received within 30 days of the date of directions for program enhancement.
necessary for the proper performance of this publication. The primary objectives of the study are
the function of the agency, including Dated: November 7, 2007. to determine if GRIP awards (1) promote
whether the information will have John J. McGowan, productive re-entry of NIH-trained
practical utility; (2) Evaluate the Deputy Director for Science Management foreign investigators into their home
accuracy of the agency’s estimate of the NIAID. countries, (2) increase the research
burden of the proposed collection of [FR Doc. E7–23183 Filed 11–29–07; 8:45 am] capacity of the international scientists
information, including the validity of BILLING CODE 4140–01–P and institution, and (3) stimulate
the methodology and assumptions used; research on a wide variety of high
(3) Enhance the quality, utility, and priority health-related issues. The
clarity of the information to be DEPARTMENT OF HEALTH AND findings will provide valuable
collected; and (4) Minimize the burden HUMAN SERVICES information concerning: (1) Specific
of the collection of information on those research advances attributable to GRIP
who are to respond, including the use National Institutes of Health
support; (2) specific capacity and career
of appropriate automated, electronic, Proposed Collection; Comment enhancing advances that are attributable
mechanical, or other technological Request; Process Evaluation of the to GRIP; (3) policy implications for GRIP
collection techniques or other forms of Global Health Research Initiative at the program level based on survey
information technology. Program for New Foreign Investigators responses, such as successes and
Direct Comments to OMB: Written (GRIP) challenges of the program’s
comments and/or suggestions regarding implementation, the GRIP support
SUMMARY: In compliance with the
the item(s) contained in this notice, mechanism, etc. Frequency of Response:
requirement of section 3506(2)(A) of
especially regarding the estimated Once. Affected Public: None. Type of
the Paperwork Reduction Act of 1995,
public burden and associated response for opportunity for public comment on Respondents: Foreign researchers. The
time, should be directed to the: Office proposed data collection projects, the annual reporting burden is as follows:
of Management and Budget, Office of Fogarty International Center (FIC), the Estimated Number of Respondents: 101;
Regulatory Affairs, New Executive National Institutes of Health (NIH), will Estimated Number of Responses per
Office Building, Room 10235, publish periodic summaries of proposed Respondent: 1; Average Burden Hours
Washington, DC 20503, Attention: Desk projects to be submitted to the Office of Per Response: 0.50; and Estimated Total
Officer for NIH. To request more Management and Budget (OMB) for Annual Burden Hours Requested: 50.5.
information on the proposed project or review and approval. The annualized cost to respondents is
to obtain a copy of the data collection Proposed Collection: Title: Process estimated at: $656.50. There are no
plans and instruments, contact evaluation of the Global Health Capital Costs to report. There are no
Katharine Kripke, Assistant Director, Research Initiative Program for New Operating or Maintenance Costs to
Vaccine Research Program, Division of Foreign Investigators (GRIP). Type of report. Table 1 and Table 2 respectively
AIDS, NIAID, NIH, 6700B Rockledge Information Collection Request: NEW. present data concerning the burden
Dr., Bethesda, MD 20892–7628, or call Need and Use of Information Collection: hours and cost burdens for this data
non-toll-free number 301–402–0846, or This study will assess the outputs of the collection.
rwilkins on PROD1PC63 with NOTICES

VerDate Aug<31>2005 16:27 Nov 29, 2007 Jkt 214001 PO 00000 Frm 00042 Fmt 4703 Sfmt 4703 E:\FR\FM\30NON1.SGM 30NON1
 67738 Federal Register / Vol. 72, No. 230 / Friday, November 30, 2007 / Notices

TABLE 1.—ANNUALIZED ESTIMATE OF HOUR BURDEN

Average time
Number of Frequency of Total hour
Type of respondents for response
respondents response burden *
(hr)

GRIP Awardees ............................................................................................... 101 1 0.50 50.5

Total .......................................................................................................... 101 1 0.50 50.5

* Total Burden = N Respondents × Response Frequency × minutes to complete/60.

TABLE 2.—ANNUALIZED COST TO RESPONDENTS

Approximate Total
Number of Frequency of
Type of respondents hourly wage respondent
respondents response rate/hr cost *

GRIP Awardees ............................................................................................... 101 1 $13 656.50

Total .......................................................................................................... 101 1 13 656.50

* Total Respondent Cost = N Respondents × Response Frequency × minutes to complete/60 × hourly rate.

Request for Comments: Written DEPARTMENT OF HEALTH AND Wip1 activity has also been shown to
comments and/or suggestions from the HUMAN SERVICES have a suppressive effect on the tumor
public and affected agencies are invited suppressor p53. This suggested that
on one or more of the following points: National Institutes of Health inhibition of Wip1 could be of
(1) Evaluate whether the proposed therapeutic value in the treatment of
collection of information is necessary Government-Owned Inventions; cancer.
for the proper performance of the Availability for Licensing
NIH inventors have developed small
function of the agency, including AGENCY: National Institutes of Health, molecules that simulate the structure of
whether the information will have Public Health Service, HHS. the amino acid sequence that Wip1
practical utility; (2) Evaluate the recognizes. The structure of the small
ACTION: Notice.
accuracy of the agency’s estimate of the molecules allows for specific targeting
burden of the proposed collection of SUMMARY: The inventions listed below to Wip1. These small molecules have
information, including the validity of are owned by an agency of the U.S. the ability to significantly inhibit Wip1
the methodology and assumptions used; Government and are available for phosphatase activity at the micromolar
(3) Enhance the quality, utility, and licensing in the U.S. in accordance with level. As a result, these small molecules
clarity of the information to be 35 U.S.C. 207 to achieve expeditious can be used in the design of
collected; and (4) Minimize the burden commercialization of results of therapeutics for cancers that
of the collection of information on those federally-funded research and overexpress Wip1.
who are to respond, including the use development. Foreign patent Applications: Treatment of cancer,
of appropriate automated, electronic, applications are filed on selected including but not limited to breast
mechanical, or other technological inventions to extend market coverage cancer, ovarian cancer and
collection techniques or other forms of for companies and may also be available neuroblastoma.
information technology. for licensing. Can be used either alone or in
FOR FURTHER INFORMATION CONTACT: To ADDRESSES: Licensing information and combination with other known anti-
request more information on the copies of the U.S. patent applications cancer therapeutics.
proposed project or to obtain a copy of listed below may be obtained by writing Advantages: Structure of the inhibitor
the data collection plans and to the indicated licensing contact at the allows targeting of Wip1 without
instruments, contact Dr. Linda Kupfer, Office of Technology Transfer, National inhibition of related phosphatases and
Fogarty International Center, National Institutes of Health, 6011 Executive their biological processes, possibly
Institutes of Health, 16 Center Drive, Boulevard, Suite 325, Rockville, leading to fewer undesired effects
Bethesda, MD 20892, or call non-toll- Maryland 20852–3804; telephone: 301/ during treatment.
free number 301–496–3288, or e-mail 496–7057; fax: 301/402–0220. A signed Small molecules are stable and have
your request, including your address to: Confidential Disclosure Agreement will the ability to effectively penetrate cells.
kupferl@mail.nih.gov. be required to receive copies of the Can be applied to many different
Comments Due Date: Comments patent applications. types of cancer.
regarding this information collection are A Family of Small Molecules for Benefits: The current lack of Wip1
best assured of having their full effect if Selective Inhibition of Wip1 inhibitors means that development of
received within 60 days of the date of Phosphatase the small molecules could lead to the
this publication. occupation of a significant position in
Description of Technology: The Wip1
Dated: November 20, 2007. phosphatase acts on proteins containing the cancer therapeutic market.
rwilkins on PROD1PC63 with NOTICES

Timothy Tosten, a particular phosphorylated amino acid The successful inhibition of a new
Executive Officer, FIC, National Institutes of sequence. Studies have shown that target in cancer therapy could provide
Health. Wip1 is overexpressed in a number of far-reaching social benefit in the
[FR Doc. E7–23235 Filed 11–29–07; 8:45 am] human cancers, including breast cancer, treatment of multiple cancers.
BILLING CODE 4140–01–P neuroblastoma and ovarian cancer. Inventors: Ettore Appella et al. (NCI).

VerDate Aug<31>2005 16:27 Nov 29, 2007 Jkt 214001 PO 00000 Frm 00043 Fmt 4703 Sfmt 4703 E:\FR\FM\30NON1.SGM 30NON1